SEATTLE–(BUSINESS WIRE)–Today results from the Salutaris Medical Devices, Inc. (SalutarisMD®) wet age-related Macular Degeneration (wet AMD) Distance of Choroid Study (DOCS) were featured in two presentations at the Association for Research in Vision and Ophthalmology, Inc. (ARVO) Annual Meeting. The first poster, by Dr. Kamaljit Balaggan, presented clinical results informing an upcoming interventional study employing the SalutarisMD® novel episcleral brachytherapy device for treatment of wet
SEATTLE — At the Association for Research in Vision and Ophthalmology meeting, Jill Hopkins, MD, medical director at Genentech, describes the company’s LADDER trial, an ongoing phase 2 trial whose purpose is to compare monthly intravitreal injections of ranibizumab in patients with wet age-related macular degeneration with long-term delivery of ranibizumab delivered via the company’s port delivery system.
SEATTLE — At the Association for Research in Vision and Ophthalmology meeting, Marco A. Zarbin, MD, PhD, discusses a review of randomized clinical trials of anti-VEGF agents for treating diabetic macular edema, including RISE, RIDE, VIVID, VISTA, RESTORE, Protocol T and Protocol S. The review found that both aflibercept and ranibizumab were “equally effective” in inducing a two-step regression in diabetic retinopathy, durability of the anti-VEGFs was “almost identical,” and incidence of systemic side effects “was comparable” in all the studies, Zarbin said.
SEATTLE — Full-field electroretinograms in patients treated with ocriplasmin changed normally, and treated patients with abnormal ERGs reversed to normal by 2 years, according to a poster presented here. The OASIS phase 3b clinical trial assessed long-term outcomes in patients with symptomatic vitreomacular adhesion (VMA), and this substudy evaluated “the relationship of ERG changes with anatomic and visual outcomes for up to 24 months after a single injection of ocriplasmin 0.125 mg,” Joseph I. Markoff, MD, said at the Association for Research in Vision and Ophthalmology meeting.
SEATTLE – “With every diopter of increase in myopia, you have an increased risk of ocular pathology,” according to Arthur Back, BOptom, PhD, FAAO.Back, chief technology officer for CooperVision, told Primary Care Optometry News in an interview here at the Association for Research in Vision and Ophthalmology meeting that the company is working on a solution to control the progression of myopia in children through the use of daily disposable contact lenses.
SEATTLE – “With every diopter of increase in myopia, you have an increased risk of ocular pathology,” according to Arthur Back, BOptom, PhD, FAAO.Back, chief technology officer for CooperVision, told Primary Care Optometry News in an interview here at the Association for Research in Vision and Ophthalmology meeting that the company is working on a solution to control the progression of myopia in children through the use of daily disposable contact lenses.